Search Results

Deals

Takeda Completes its Acquisition of TiGenix Following Expiration of the Squeeze-out Period

TiGenix becomes a wholly owned subsidiary of Takeda

July 31, 2018

·

8 min read

Policy

Takeda and TiGenix Announce Results of First Acceptance Period for the Voluntary and Conditional Public Takeover Bid of TiGenix and Commencement of Second Acceptance Period

Takeda Pharmaceutical Company Limited and TiGenix NV today announced the results of the first acceptance period of Takeda’s previously announced tender offer in cash for all outstanding ordinary shares, warrants and American Depositary Shares of TiGenix that are not yet owned by Takeda and its affiliates.

June 6, 2018

·

12 min read

Business

Mesoblast Grants Tigenix an Exclusive Global Patent License to Use Adipose-Derived Mesenchymal Stem Cells in the Local Treatment of Fistulae

The agreement includes the right for TiGenix to grant sub-licenses to affiliates and third parties, including TiGenix’s current development and commercialization partner ex-United States.

December 15, 2017

·

8 min read

Deals

Busy Takeda Takes Out Tigenix in $630M Deal

Shares of TiGenix shot up more than 72 percent in pre-market trading after the deal was announced.

January 5, 2018

·

2 min read

·

Alex Keown

TiGenix: Transparency Information - Feb. 7, 2018

Following the issuance of 413,283 new shares on February 6, 2018 resulting from the exercise of 413,283 warrants of TiGenix NV, the transparency data have changed as follows (status on February 6, 2018):

February 7, 2018

·

3 min read

Tigenix Announces Approval of Trade Name for Lead Development Candidate Cx601 in Europe

The trade name Alofisel, a registered trademark owned by TiGenix, will be used from now onwards.

November 16, 2017

·

5 min read

Drug Development

Tigenix Granted Orphan Drug Designation From the U.S. FDA for Cx601

TiGenix started a global pivotal Phase III clinical trial in the first half of 2017.

October 23, 2017

·

6 min read

Drug Development

Cryoport to Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of SEPCELL for the Treatment of Sepsis

TiGenix aims to recruit 180 patients in at least 50 centers for the randomized double-blind placebo controlled SEPCELL study.

February 5, 2018

·

4 min read

JPMorgan Chase & Co Notifies 3.12% Shareholding in TiGenix

TiGenix publishes today a transparency notification pursuant to Article 14 of the Belgian Law of May 2, 2007 regarding the publication of major holdings in issuers whose securities are admitted to trading on a regulated market and including various provisions.

November 27, 2017

·

2 min read

Drug Development

TiGenix Granted Orphan Drug Designation From the U.S. FDA for Cx601

TiGenix NV announces that the FDA has granted orphan drug designation (ODD) to Cx601 for the treatment of patients with fistulizing Crohn´s disease.

October 23, 2017

·

4 min read